Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of SAR443122 in moderate to severe ulcerative colitis
jRCT2031230203Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing SAR443122 with Placebo (2 arms). Primary endpoint: Clinical remission by modified Mayo Score at Week 12. Started Jan 2024; status: active, not recruiting.
02
Drugs
eclitasertib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031230203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230203.